Workflow
艾帕洛利托沃瑞利单抗注射液
icon
Search documents
生物制造行业周刊:配套政策持续完善,生物制造进入产业化加速关键期
Chan Ye Xin Xi Wang· 2025-08-27 06:43
Key Policies - The Ministry of Industry and Information Technology and the National Health Commission have initiated a call for innovative biomanufacturing technology applications in the food processing sector, focusing on areas such as food raw materials, additives, and related products [1] - Hainan Province has introduced measures to support the high-quality development of the biopharmaceutical industry, including financial rewards for product R&D and clinical trials ranging from 400,000 to 10 million yuan [2][3] - Hainan encourages mergers and acquisitions among local pharmaceutical companies, providing interest subsidies for bank loans related to these activities [2] Key Events - The 2025 China Biomanufacturing Technology Innovation Forum will be held in Changde, Hunan, on September 25-26, aiming to promote deep integration of technology innovation and industry [10][12] - The fourth Synthetic Biology and Green Biomanufacturing Conference was successfully held in Ningbo, highlighting AI technology as a new engine for synthetic biology [21] - A biomanufacturing pilot platform alliance has been launched in Binhai New Area, focusing on fermentation, cell, nucleic acid, and vaccine directions [22] Key Companies - Qilu Pharmaceutical has launched 15 biological drugs, including a globally first PD-1/CTLA-4 dual-function combination antibody, marking a significant achievement in China's biopharmaceutical innovation [25][26] - Shenzhen Jingtai Technology's incubated company, Signet Therapeutics, has been nominated for the 2025 Prix Galien USA for its AI-driven gastric cancer drug, showcasing the potential of AI in drug development [29][30] - Saiye Bio has been recognized for its AI application in antibody drug discovery, reflecting the growing trend of integrating AI in biomanufacturing [46]
医药工业百强企业出口回升显著,多部委释放“出海”利好信号
Di Yi Cai Jing· 2025-07-07 12:06
2024年,在业绩增长持续承压的大背景下,前100位企业仍在持续加码创新,平均研发费用达8.3亿元, 同比增长6.3%。 过去一年,我国医药行业继续承压,医药工业百强企业的总体收入已连续三年出现下滑,但百强企业出 口交货值显著回升等行业积极势头也开始显现。 与此同时,百强企业持续加码创新。2024年,百强企业平均研发费用达8.3亿元,再创历史新高,13家 企业研发强度超过15%;创新回报进一步显现,我国当年共获批48个创新药物,其中12个来自百强企 业,多家本土创新药企凭借国际授权收入,拉动位次上涨。 近日,在2025年(第42届)全国医药工业信息年会上,中国医药工业信息中心公布的《2024年度中国医 药工业主营业务收入前100位企业》显示了上述信息。 业界观点认为,前100位企业的业绩表现和结构特征是医药行业运行状况和结构性变化的重要投射。当 前,产业生态正经历从规模增长向质量效益转变的结构性调整,在这一过程中,外资药企本土化突破、 本土企业创新转型和生物药快速布局三大趋势或将重塑头部企业竞争格局。 百强企业出口逆势上涨 "2024年度中国医药工业主营业务收入前100位企业"即行业通常所说的医药工业百强企业 ...